Bayer issues profit warning:
This article was originally published in Clinica
The German chemicals, drugs and diagnostics company Bayer has told the market that its operating profit for the second quarter would be "well below" the E938 million ($809 million) for 2000. The full year will be around E3 billion, failing to match last year's 20% increase to $3.34 billion. Its healthcare division will also fall short of last year's profits, the company said.
You may also be interested in...
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.
US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.